Home › Melanoma › Tennessee
Melanoma clinical trials in Tennessee
42 studies for Melanoma are looking for participants at sites in Tennessee.
Cities in Tennessee
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Tennessee Oncology, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06270706A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Tennessee Oncology - Chattanooga, Chattanooga
- University of Tennessee Medical Center, Knoxville
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT06246916Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- University of Tennessee Health Science Center, Knoxville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT04198766Phase 1 Study of PF-08046033 in Advanced Solid Tumors
- Sarah Cannon Research Institute- Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07519655A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Tennessee Oncology, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06150664Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
- Baptist Memorial Hospital for Women, Memphis
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06418204SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
- Sarah Cannon Research Institute - Oncology Partners, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07857616A Study of BI 3810944 in Patients With Advanced Cancer
- Tennessee Oncology, PLLC - Elliston Place Plaza DDU, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07224425Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT07751042A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Erlanger Health, Inc, Chattanooga
- The West Clinic, Germantown
- SCRI Oncology Partners, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06330064A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06172478Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Institute, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07287917A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 136, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT05914116DESTINY-PANTUMOUR04
- Research Site, Nashville
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- Baptist Cancer Center, Bartlett
- SCRI Oncology Partners, Nashville
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT05727904A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
- East Tennessee Childrens Hospital, Knoxville
- Saint Jude Children's Research Hospital, Memphis
RecruitingPhase 2
Up to age 25 · All sexes · Updated Sep 24, 2026 · NCT07621614Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Vanderbilt University/Ingram Cancer Center, Nashville
RecruitingPhase 3
Ages 75 and older · All sexes · Updated Sep 24, 2026 · NCT07068074R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1
Ages 18 to 80 · All sexes · Updated Sep 18, 2026 · NCT06398418Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05267626A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- Sarah Cannon Research Institute-Tennessee Oncology, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT04913285Project: Every Child for Younger Patients With Cancer
- T C Thompson Children's Hospital, Chattanooga
- East Tennessee Childrens Hospital, Knoxville
- Saint Jude Children's Research Hospital, Memphis
- and 2 more
RecruitingObservational study
Up to age 25 · All sexes · Updated Aug 25, 2026 · NCT02402244Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Saint Jude Children's Research Hospital, Memphis
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT04895709Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
- Tennessee Oncology, PLLC, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT06425926A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626Familial Investigations of Childhood Cancer Predisposition
- St. Jude Children's Research Hospital, Memphis
RecruitingObservational study
All ages · All sexes · Updated Jun 17, 2026 · NCT03050268A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Jun 15, 2026 · NCT06940739Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- The Sarah Cannon Research Institute/Tennessee Oncology, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 8, 2026 · NCT03947385B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
- St. Jude Children's Research Hospital, Memphis
RecruitingPhase 1
Up to age 21 · All sexes · Updated May 19, 2026 · NCT04897321Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Tennessee Oncology, Chattanooga
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 15, 2026 · NCT05379985Neoadjuvant Darovasertib in Primary Uveal Melanoma
- SCRI Oncology Partners, Nashville
- Vanderbilt Eye Institute, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT07015190Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
- Vanderbilt-Ingram Cancer Center, Nashville
Recruiting
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT07555210A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 20, 2026 · NCT06326411A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- The West Clinic, PLLC dba West Cancer Center, Germantown
- University of Tennessee Medical Center, Knoxville
- Sarah Cannon Research Institute, Nashville
- and 1 more
RecruitingPhase 2/3
All ages · All sexes · Updated Apr 2, 2026 · NCT06581406Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- University of Tennessee Medical Center, Knoxville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Feb 25, 2026 · NCT05549297Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
- Vanderbilt-Ingram Cancer Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT04903119Molecular Analysis of Childhood and Adolescent Melanocytic Lesions
- St. Jude Children's Research Hospital, Memphis
RecruitingObservational study
Up to age 18 · All sexes · Updated Nov 10, 2025 · NCT02775643SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
- Vanderbitl-Ingram Cancer Center, Nashville
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 19, 2025 · NCT01205815From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.